vs

Side-by-side financial comparison of STANDARD BIOTOOLS INC. (LAB) and SIFCO INDUSTRIES INC (SIF). Click either name above to swap in a different company.

SIFCO INDUSTRIES INC is the larger business by last-quarter revenue ($24.0M vs $19.6M, roughly 1.2× STANDARD BIOTOOLS INC.). SIFCO INDUSTRIES INC runs the higher net margin — 7.5% vs -177.4%, a 184.9% gap on every dollar of revenue. On growth, SIFCO INDUSTRIES INC posted the faster year-over-year revenue change (14.8% vs -11.5%). SIFCO INDUSTRIES INC produced more free cash flow last quarter ($8.0M vs $-23.1M). Over the past eight quarters, SIFCO INDUSTRIES INC's revenue compounded faster (8.1% CAGR vs -12.2%).

Standard BioTools Inc., previously known as Fluidigm Corp., is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits (IFCs), and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications.

SIFCO Industries, Inc. (SIFCO), is a global metal component manufacturer based in Cleveland, Ohio.

LAB vs SIF — Head-to-Head

Bigger by revenue
SIF
SIF
1.2× larger
SIF
$24.0M
$19.6M
LAB
Growing faster (revenue YoY)
SIF
SIF
+26.3% gap
SIF
14.8%
-11.5%
LAB
Higher net margin
SIF
SIF
184.9% more per $
SIF
7.5%
-177.4%
LAB
More free cash flow
SIF
SIF
$31.1M more FCF
SIF
$8.0M
$-23.1M
LAB
Faster 2-yr revenue CAGR
SIF
SIF
Annualised
SIF
8.1%
-12.2%
LAB

Income Statement — Q3 FY2025 vs Q1 FY2026

Metric
LAB
LAB
SIF
SIF
Revenue
$19.6M
$24.0M
Net Profit
$-34.7M
$1.8M
Gross Margin
48.5%
21.6%
Operating Margin
-168.5%
10.7%
Net Margin
-177.4%
7.5%
Revenue YoY
-11.5%
14.8%
Net Profit YoY
-28.8%
177.3%
EPS (diluted)
$-0.09
$0.29

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LAB
LAB
SIF
SIF
Q4 25
$24.0M
Q3 25
$19.6M
$22.8M
Q2 25
$21.8M
$22.1M
Q1 25
$40.8M
$19.0M
Q4 24
$20.9M
Q3 24
$22.1M
$21.7M
Q2 24
$22.5M
$22.0M
Q1 24
$45.5M
$20.5M
Net Profit
LAB
LAB
SIF
SIF
Q4 25
$1.8M
Q3 25
$-34.7M
$-429.0K
Q2 25
$-33.5M
$3.4M
Q1 25
$-26.0M
$-1.4M
Q4 24
$-2.3M
Q3 24
$-26.9M
$-443.0K
Q2 24
$-45.7M
$72.0K
Q1 24
$-32.2M
$-1.6M
Gross Margin
LAB
LAB
SIF
SIF
Q4 25
21.6%
Q3 25
48.5%
9.6%
Q2 25
48.8%
26.7%
Q1 25
48.4%
8.3%
Q4 24
4.4%
Q3 24
54.9%
10.7%
Q2 24
46.1%
12.3%
Q1 24
53.1%
7.3%
Operating Margin
LAB
LAB
SIF
SIF
Q4 25
10.7%
Q3 25
-168.5%
-1.7%
Q2 25
-118.1%
14.8%
Q1 25
-80.8%
-4.1%
Q4 24
-9.2%
Q3 24
-120.9%
-1.5%
Q2 24
-134.5%
0.7%
Q1 24
-132.2%
-6.5%
Net Margin
LAB
LAB
SIF
SIF
Q4 25
7.5%
Q3 25
-177.4%
-1.9%
Q2 25
-153.7%
15.4%
Q1 25
-63.8%
-7.3%
Q4 24
-11.1%
Q3 24
-122.0%
-2.0%
Q2 24
-203.3%
0.3%
Q1 24
-70.6%
-7.8%
EPS (diluted)
LAB
LAB
SIF
SIF
Q4 25
$0.29
Q3 25
$-0.09
$-0.07
Q2 25
$-0.09
$0.56
Q1 25
$-0.07
$-0.23
Q4 24
$-0.38
Q3 24
$-0.07
$-0.07
Q2 24
$-0.12
$0.01
Q1 24
$-0.27
$-0.27

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LAB
LAB
SIF
SIF
Cash + ST InvestmentsLiquidity on hand
$129.4M
$1.1M
Total DebtLower is stronger
$39.0K
Stockholders' EquityBook value
$399.7M
$38.7M
Total Assets
$539.6M
$74.9M
Debt / EquityLower = less leverage
0.00×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LAB
LAB
SIF
SIF
Q4 25
$1.1M
Q3 25
$129.4M
$491.0K
Q2 25
$158.6M
$2.0M
Q1 25
$150.9M
$1.9M
Q4 24
$3.1M
Q3 24
$210.6M
$1.7M
Q2 24
$269.8M
$3.4M
Q1 24
$287.1M
$2.5M
Total Debt
LAB
LAB
SIF
SIF
Q4 25
$39.0K
Q3 25
$51.0K
Q2 25
Q1 25
Q4 24
Q3 24
$55.2M
$0
Q2 24
$55.1M
$3.6M
Q1 24
$55.0M
$4.1M
Stockholders' Equity
LAB
LAB
SIF
SIF
Q4 25
$38.7M
Q3 25
$399.7M
$36.9M
Q2 25
$424.5M
$35.8M
Q1 25
$454.6M
$32.4M
Q4 24
$33.7M
Q3 24
$489.3M
$30.4M
Q2 24
$510.3M
$29.8M
Q1 24
$577.3M
$29.7M
Total Assets
LAB
LAB
SIF
SIF
Q4 25
$74.9M
Q3 25
$539.6M
$73.4M
Q2 25
$557.0M
$77.3M
Q1 25
$579.6M
$78.8M
Q4 24
$81.0M
Q3 24
$681.5M
$104.6M
Q2 24
$708.7M
$106.3M
Q1 24
$777.7M
$104.2M
Debt / Equity
LAB
LAB
SIF
SIF
Q4 25
0.00×
Q3 25
0.00×
Q2 25
Q1 25
Q4 24
Q3 24
0.11×
0.00×
Q2 24
0.11×
0.12×
Q1 24
0.10×
0.14×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LAB
LAB
SIF
SIF
Operating Cash FlowLast quarter
$-22.2M
$8.1M
Free Cash FlowOCF − Capex
$-23.1M
$8.0M
FCF MarginFCF / Revenue
-118.1%
33.3%
Capex IntensityCapex / Revenue
4.5%
0.4%
Cash ConversionOCF / Net Profit
4.51×
TTM Free Cash FlowTrailing 4 quarters
$-111.1M
$11.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LAB
LAB
SIF
SIF
Q4 25
$8.1M
Q3 25
$-22.2M
$726.0K
Q2 25
$-20.7M
$371.0K
Q1 25
$-30.3M
$2.8M
Q4 24
$-3.8M
Q3 24
$-27.9M
$857.0K
Q2 24
$-39.0M
$382.0K
Q1 24
$-62.5M
$-3.2M
Free Cash Flow
LAB
LAB
SIF
SIF
Q4 25
$8.0M
Q3 25
$-23.1M
$566.0K
Q2 25
$-22.6M
$310.0K
Q1 25
$-35.3M
$2.7M
Q4 24
$-3.9M
Q3 24
$-30.1M
$580.0K
Q2 24
$-41.0M
$-175.0K
Q1 24
$-63.3M
$-3.9M
FCF Margin
LAB
LAB
SIF
SIF
Q4 25
33.3%
Q3 25
-118.1%
2.5%
Q2 25
-103.6%
1.4%
Q1 25
-86.6%
14.1%
Q4 24
-18.8%
Q3 24
-136.4%
2.7%
Q2 24
-182.2%
-0.8%
Q1 24
-138.9%
-18.9%
Capex Intensity
LAB
LAB
SIF
SIF
Q4 25
0.4%
Q3 25
4.5%
0.7%
Q2 25
8.7%
0.3%
Q1 25
12.4%
0.8%
Q4 24
0.5%
Q3 24
10.2%
1.3%
Q2 24
8.6%
2.5%
Q1 24
1.7%
3.3%
Cash Conversion
LAB
LAB
SIF
SIF
Q4 25
4.51×
Q3 25
Q2 25
0.11×
Q1 25
Q4 24
Q3 24
Q2 24
5.31×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

LAB
LAB

Consumables$8.7M45%
Services And Other Revenue$5.8M29%
Instruments$5.1M26%

SIF
SIF

Fixed Wing Aircraft Revenue$10.5M44%
Commercial Revenue$8.7M36%
Commercial Product And Other Revenue$2.8M12%
Commercial Space$1.1M5%
Other$840.0K4%

Related Comparisons